AP26113, A POTENT ALK INHIBITOR, IS ALSO ACTIVE AGAINST EGFR T790M IN MOUSE MODELS OF NSCLC

被引：0
|
作者：
Miret, Juan J. [1 ]
Wang, Frank [1 ]
Anjum, Rana [1 ]
Zhang, Sen [1 ]
Keats, Jeffrey [1 ]
Cookson, Michelle [1 ]
Ning, Yaoyu [1 ]
Wardwell, Scott [1 ]
Moran, Lauren [1 ]
Mohemmad, Qurish [1 ]
Wang, Yihan [1 ]
Qi, Jiwei [1 ]
Squillace, Rachel [1 ]
Narasimhan, Narayana [1 ]
Dalgarno, David [1 ]
Clackson, Tim [1 ]
Shakespeare, William [1 ]
Rivera, Victor [1 ]
机构：
[1] ARIAD Pharmaceut Inc, Biol, Cambridge, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
EGFR T790M; reversible kinase inhibitor; AP26113; ALK;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S577 / S578
页数：2
相关论文
共 50 条
  • [21] Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK plus non-small cell lung cancer (NSCLC).
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA
    Gettinger, S.
    Bazhenova, L.
    Salgia, R.
    Langer, C.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G. J.
    Narasimhan, N. I.
    Dorer, D. J.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [23] Discovery of highly potent and selective EGFR(T790M/L858R) TKIs against NSCLC based on molecular dynamic simulation
    Yang, Tingting
    Zhang, Wenjuan
    Cao, Shengjie
    Sun, Shiyang
    Cai, Xu
    Xu, Lei
    Li, Pengyun
    Zheng, Zhibing
    Li, Song
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 228
  • [24] ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test
    Freitas, H. C.
    Park, K.
    Kim, D-W.
    Tiseo, M.
    Hochmair, M. J.
    Chang, G-C.
    Shi, Y-K.
    Moran, T.
    Chen, Y.
    Laskin, J.
    Solomon, B.
    Miranda, M.
    Rigas, J.
    Cheema, P. K.
    Kim, S-W.
    ANNALS OF ONCOLOGY, 2018, 29 : 149 - 149
  • [25] Lung Adenocarcinoma with Double Heterozygote EGFR mutation and Combined Resistance: ALK Translocation and EGFR T790M
    Denninghoff, V.
    Wainsztein, V.
    Cuello, M. T.
    Recondo, G.
    Rojas Bilbao, E.
    Avagnina, A.
    Recondo, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S179 - S179
  • [26] EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK plus NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES
    Kerstein, D.
    Gettinger, S.
    Gold, K.
    Langer, C. J.
    Shaw, A. T.
    Bazhenova, L. A.
    Salgia, R.
    Dorer, D. J.
    Conlan, M. G.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [27] Discovery of brigatinib (AP26113), a phosphine oxide-based, potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants
    Huang, Weisheng
    Li, Feng
    Cai, Lisi
    Xu, Yongjin
    Zhang, Sen
    Wardwell, Scott
    Ning, Yaoyu
    Kohlmann, Anna
    Zhou, Tianjun
    Ye, Yihua Emily
    Zhu, Xiaotian
    Narasimhan, Narayana I.
    Clackson, Tim
    Rivera, Victor M.
    Dalgarno, David
    Shakespeare, William
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [28] Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
    Zhou, Wenjun
    Ercan, Dalia
    Chen, Liang
    Yun, Cai-Hong
    Li, Danan
    Capelletti, Marzia
    Cortot, Alexis B.
    Chirieac, Lucian
    Iacob, Roxana E.
    Padera, Robert
    Engen, John R.
    Wong, Kwok-Kin
    Eck, Michael J.
    Gray, Nathanael S.
    Jaenne, Pasi A.
    NATURE, 2009, 462 (7276) : 1070 - 1074
  • [29] Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
    Wenjun Zhou
    Dalia Ercan
    Liang Chen
    Cai-Hong Yun
    Danan Li
    Marzia Capelletti
    Alexis B. Cortot
    Lucian Chirieac
    Roxana E. Iacob
    Robert Padera
    John R. Engen
    Kwok-Kin Wong
    Michael J. Eck
    Nathanael S. Gray
    Pasi A. Jänne
    Nature, 2009, 462 : 1070 - 1074
  • [30] Successful treatment with osimertinib for leptomeningeal carcinomatosis from NSCLC with the EGFR T790M mutation
    Yoshimura, Naruo
    Takahashi, Hidenori
    Kurosawa, Emiko
    Tanaka, Akiko
    Ebina, Masahito
    Ohrui, Takashi
    ANNALS OF ONCOLOGY, 2019, 30 : 139 - 139
12345